Flexion Therapeutics (NASDAQ:FLXN) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.23, Bloomberg Earnings reports. The firm had revenue of $2.19 million during the quarter, compared to analysts’ expectations of $1.99 million.
NASDAQ FLXN opened at $25.43 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 13.02 and a quick ratio of 12.96. The company has a market cap of $968.71 million, a PE ratio of -6.11 and a beta of 0.82.
A number of brokerages recently issued reports on FLXN. ValuEngine raised shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, April 27th. Wells Fargo reissued a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, April 26th. BidaskClub raised shares of Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 28th. Berenberg Bank began coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 price objective for the company. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (down previously from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $99.00.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.